01053-X/asset/826330f0-5581-4d6d-8f45-2192fe6ac242/main.assets/gr2_lrg.jpg)
retatrutide triple agonist glp-1 gip glucagon Retatrutide, a GIP, and receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Retatrutide Api Triple Gip Glp-1
Description
The key findings include: 9 total patients (mean age 57.4 years, range 37-77 years) developed significant vision complications
Identification of potent 11mer glucagon-like peptide-1 receptor agonist peptides with novel C-terminal amino acids: homohomophenylalanine analogs
doi:10.1056/NEJMoa2206038
[DOI] [PubMed] [Google Scholar] 64.Berning P., Adhikari R., Schroer A
After two years (120 weeks), the patients retained roughly one-third of their original weight loss (5.6% of the original 17.3% loss)
CagriSema leverages two individually validated components and is further along in development (phase 3 completed)
